Clinical Trial Detail

NCT ID NCT01518413
Title Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Children's Research Institute
Indications

rhabdomyosarcoma

neuroblastoma

osteosarcoma

bone Ewing's sarcoma

extraosseous Ewing's sarcoma

brain cancer

sarcoma

Advanced Solid Tumor

Therapies

Irinotecan + Sorafenib

Age Groups: adult child

No variant requirements are available.